Neuren Pharmaceuticals Limited

NEU

NZNEUE0001S8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 04:10:15 13/02/26 pm AEDT			5-day change	1st Jan Change
12.75 ^AUD	-6.04%		+1.84%	-31.49%

12/02	Neuren Pharmaceuticals Limited - Special Call
11/02	Neuren Pharmaceuticals Limited authorizes a Buyback Plan.	CI

Neuren Pharmaceuticals Says US FDA Provides Guidance On Clinical Study OF Drug Candidate For Treatment Of Hypoxic Ischemic Encephalopathy

Published on 02/04/2026 at 05:44 pm AEDT

MT Newswires

Latest news about Neuren Pharmaceuticals Limited

12/02	Neuren Pharmaceuticals Limited - Special Call
11/02	Neuren Pharmaceuticals Limited authorizes a Buyback Plan.	CI
11/02	Neuren Pharmaceuticals Limited announces an Equity Buyback.	CI
11/02	Neuren Pharmaceuticals announces new on-market share buy-back program	RE
11/02	Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program	MT
06/02	Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies	MT
06/02	Neuren Doses First Patient in Drug Candidate Trial for Treatment of Neurological Disorder	MT
05/02	Australian Shares Fall; Beach Energy Posts Lower Fiscal H1 Underlying Earnings, Flat Revenue	MT
05/02	Neuren Pharmaceuticals Says US Extends Rare Pediatric Disease Voucher Program	MT
04/02	Neuren Pharmaceuticals Says US FDA Provides Guidance On Clinical Study OF Drug Candidate For Treatment Of Hypoxic Ischemic Encephalopathy	MT
04/02	Neuren Pharmaceuticals Requests Trading Halt Ahead of FDA Feedback on NNZ-2591	MT
04/02	Neuren Pharmaceuticals seeks trading halt	RE
03/02	Australian Shares Rise; Credit Corp Group Posts Flat Fiscal H1 Earnings, Higher Revenue	MT
03/02	Neuren Pharmaceuticals informed of negative trend vote on MAA for trofinetide	RE
03/02	Neuren Pharmaceuticals' Rett Syndrome Drug Receives Negative Trend Vote by CHMP, Shares Fall 10%	MT

Chart Neuren Pharmaceuticals Limited

Duration

Period

NEU: Dynamic Chart

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Companyâ€™s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Employees

Sector

Pharmaceuticals

Calendar

26/02 - Q4 2025 Earnings Release (Projected)

More about the company